Back to Treatments

Treatment

Docetaxel + Cisplatin + 5-Fluorouracil (TPF Induction Chemotherapy) followed by Concurrent Chemoradiotherapy

1
Conditions
3
Trials
8,000
Participants
20%
Average Safety

Condition Evidence

Nasopharynx cancer

3 trials · 8,000 participants

89% effectiveness · 20% safety
Docetaxel + Cisplatin + 5-Fluorouracil (TPF Induction Chemotherapy) followed by Concurrent Chemoradiotherapy | DFDA